A Phase 2, Open-Label, Extension Study to Evaluate the Long- Term Safety and Efficacy of Ubenimex in Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Eiger BioPharmaceuticals, Inc.
Start Date
August 1, 2016
End Date
July 31, 2018
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Eiger BioPharmaceuticals, Inc.
Start Date
August 1, 2016
End Date
July 31, 2018